WHO strongly advises against antibody treatments for COVID-19 patients - Video
|
Overview
The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.
Today's strong recommendation replaces previous conditional recommendations for their use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as omicron.
After weighing up all the evidence, the panel judged that almost all well informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.
In the same guideline update, WHO makes a conditional recommendation for the use of the antiviral drug remdesivir in patients with severe covid-19, and a conditional recommendation against its use in patients with critical covid-19.
These recommendations are based on results from five randomised trials involving 7,643 patients, showing 13 fewer deaths per 1,000 patients with severe covid-19 taking remdesivir, but 34 more deaths per 1,000 patients with critical covid-19 taking the drug.
These new trial data provided sufficiently trustworthy evidence to demonstrate benefits in patients with severe covid-19, but not critical covid-19. The panel considered the benefits of remdesivir to be modest and of moderate certainty for key outcomes such as mortality and mechanical ventilation, resulting in a conditional recommendation.
WHO also advises that three drugs used to treat arthritis - the IL-6 receptor blockers tocilizumab or sarilumab and the JAK inhibitor baricitinib - may now be combined, in addition to corticosteroids, in patients with severe or critical covid-19.
However, the panel acknowledges some cost and resource implications associated with these drugs, which they say could exacerbate health inequities.
Reference:
Rapid Recommendations: A living WHO guideline on drugs for covid-19, The BMJ, DOI: 10.1136/bmj.m3379
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751
